Picture loading failed.

Anti-FCGRT therapeutic antibody (Pre-made Nipocalimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Nipocalimab is a fully human, aglycosylated, effectorless immunoglobulin G1 (IgG) anti-FcRN antibody that functions to reduce the levels of other IgG antibodies in the blood, including the autoantibodies that cause gMG.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-378-1mg 1mg 3090
GMP-Bios-ab-378-10mg 10mg 21890
GMP-Bios-ab-378-100mg 100mg 148000
GMP-Bios-ab-378-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-FCGRT therapeutic antibody (Pre-made Nipocalimab biosimilar,Whole mAb)
INN Name Nipocalimab
TargetFCGRT
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI Structure5whk:HL/5whj:HL
Year Proposed2019
Year Recommended2020
CompaniesMomenta
Conditions Approvedna
Conditions ActiveAutoimmune haemolytic anaemia;Haemolytic disease of newborn;Myasthenia gravis
Conditions Discontinuedna
Development Techna